Background Several studies have established the safety and efficacy of balloon guide catheters (BGCs) for large vessel occlusions. However, the utility of BGCs remains largely unexplored for distal medium vessel occlusions (DMVOs). In this study, we aim to compare the outcomes of BGC vs. Non-BGC in patients undergoing mechanical thrombectomy (MT) for DMVO.
Method This retrospective study from the Stroke Thrombectomy and Aneurysm Registry (STAR) encompassed adult patients with acute anterior cerebral artery, posterior cerebral artery, and middle cerebral artery-M2–3–4 occlusions. Procedure times, safety, recanalization, and neurological outcomes were compared between the two groups, with subgroup analysis based on first-line thrombectomy techniques.
Results A total of 1508 patients were included, with 231 patients (15.3%) in the BGC group and 1277 patients (84.7%) in the non-BGC group. The BGC group had a lower modified Thrombolysis in Cerebral Infarction (mTICI) score ≥2C (43.2% vs 52.7%, P=0.01), longer time from puncture to intracranial access (15 vs 8 min, P<0.01), and from puncture to final recanalization (97 vs 34 min, P<0.01). In the Solumbra subgroup, the first pass effect (FPE) rate was lower in the BGC group (17.4% vs 30.7%, P=0.03). Regarding clinical outcomes, the BGC group had a lower rate of distal embolization (8.8% vs 14.9%, P=0.03).
Conclusion Our study found that use of BGC in patients with DMVO was associated with lower mTICI scores, decreased FPE rates, reduced distal embolization, and longer procedure times.
Data availability statement
Data are available upon reasonable request. The data that support the findings of this study are available from the principal investigator upon reasonable request.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Twitter @yigitcs, @mahdisowlat, @PascalJabbourMD, @Starke_neurosurgery, @AdamArthurMD, @BrianHoward_MD, @rocrossa, @DrMichaelLevitt, @pnavia, @PeterKa80460001, @rdeleacymd
Contributors WB, DFK and AO contributed to the conception and design of the study. All authors were responsible for data collection. SSE and AO performed statistical analyses. All authors were involved in the interpretation of results, drafting of the article, critical revision of the article, and final approval of the version to be published. AO is responsible for the overall content as guarantor.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests The STAR Registry currently receives funding from Penumbra, Stryker, and Medtronic. HM received a lecture fee from Daiichi-Sankyo and Stryker and consulting services fee from B Braun. SY received a lecture fee from Stryker, Medtronic, Johnson and Johnson, Kaneka Medics. IM: speakers honoraria from Pfizer and Bristol-Myers Squibb. SAK: grant from Stryker for RESCUE-ICAS Registry. RMS: research is supported by the NREF, Joe Niekro Foundation, Brain Aneurysm Foundation, Bee Foundation, Department of Health Biomedical Research Grant (21K02AWD-007000), and by National Institute of Health (R01NS111119-01A1) and (UL1TR002736, KL2TR002737) through the Miami Clinical and Translational Science Institute, from the National Center for Advancing Translational Sciences and the National Institute on Minority Health and Health Disparities. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH; has an unrestricted research grant from Medtronic and Balt and has consulting and teaching agreements with Penumbra, Abbott, Medtronic, Balt, InNeuroCo, Cerenovus, Naglreiter, Tonbridge, Von Medical, and Optimize Vascular. M-NP: grants from the Swiss National Science Foundation (SNF) for the DISTAL trial (33IC30_198783) and TECNO trial (32003B_204977), grant from Bangerter-Rhyner Stiftung for the DISTAL trial; unrestricted grants for the DISTAL trial from Stryker Neurovascular Inc, Phenox GmbH, Penumbra Inc, and Rapid Medical Inc., Sponsor-PI SPINNERS trial (funded by a Siemens Healthineers AG Grant); research agreement with Siemens Healthineers AG, Local PI for the ASSIST, EXCELLENT, TENSION, COATING, SURF and ESCAPE-NEXT trials; speaker fees: Stryker Neurovascular Inc., Medtronic Inc., Penumbra Inc, Acandis GmbH, Phenox GmbH, Siemens Healthineers AG. ASA: consultant for Arsenal, Balt, Johnson and Johnson, Medtronic, Microvention, Penumbra, Perfuze, Scientia, Siemens, Stryker; research support from Balt, Medtronic, Microvention, Penumbra, and Siemens; shareholder Azimuth, Bendit, Cerebrotech, Endostream, Magneto, Mentice, Neurogami, Neuros,Perfuze, Revbio, Scientia, Serenity, Synchron, Tulavi, Vastrax, VizAI. SY: lecture fee from Stryker, Medtronic, Johnson and Johnson, Kaneka Medics. HC: consultant for Medtronic, Penumbra, and Microvention. JAG: grant support from Georgia Research Alliance, Emory Medical Care Foundation, Neurosurgery Catalyst, Consultant: Cognition, Imperative Care. DGR: consultant for Penumbra, Balt, Microvention, Phenox. CM: consultant for Stryker, Medtronic, Microvention, Penumbra, and Silk Road Medical; speaker for Penumbra and Silk Road Medical Contact PI for NIH Grant R21NS128641. MSP: consultant for Medtronic. MRL: unrestricted educational grants from Medtronic and Stryker; consulting agreement with Medtronic, Aeaean Advisers, and Metis Innovative; equity interest in Proprio, Cerebrotech, Apertur, Stereotaxis, Fluid Biomed, and Hyperion Surgical; editorial boards of Journal of NeuroInterventional Surgery and Frontiers in Surgery. RW: consultant for Medtronic, Stryker, and Synaptive Medical. PN: consultant for Penumbra, Medtronic, Stryker, Cerenovus and Balt; grants from the NIH (1U18EB029353-01) and unrestricted educational grants from Medtronic and Siemens; consultant for Imperative Care and Stryker Neurovascular; stock ownership in Vena Medical. RDL: PI for Imperative Trial; research grants from Siemens Healthineers and Kaneka Medical; consultant for Cerenovus, Stryker Neurovascular and Scientia Vascular; minor equity interest Vastrax, Borvo Medical, Synchron, Endostream, Von Vascular. SAC: consultant and proctor for Medtronic and Microvention. AMS: research support from Penumbra, Stryker, Medtronic, Rapid AI, Avail; consultant for Penumbra, Stryker, Terumo, and RapidAI Equity Avail. WB: equity in Nested Knowledge, Superior Medical Editors, Piraeus Medical, Sonoris Medical, and MIVI Neurovascular; receives royalties from Medtronic and Balloon Guide Catheter Technology; receives consulting fees from Medtronic, Stryker, Imperative Care, MicroVention, MIVI Neurovascular, Cerenovus, Asahi, and Balt; serves in a leadership or fiduciary role for MIVI Neurovascular, Marblehead Medical LLC, Interventional Neuroradiology (editor-in-chief), Piraeus Medical, and WFITN.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.